EcoDrugPlus


Trade Names	MAGNEVIST
Synonyms	Dimeglumine gadopentetate Gadopentate dimeglumine Gadopentetate dimeglumine Gadopentetic acid Gadopentetic acid dimeglumine salt Magnevist Meglumine gadopentetate SH L 451 A SH-L 451 A SH-L-451-A SHL-451A
Status
Molecule Category	UNKNOWN
UNII	RH248G8V27

Trade Names

MAGNEVIST

Synonyms

Dimeglumine gadopentetate

Gadopentate dimeglumine

Gadopentetate dimeglumine

Gadopentetic acid

Gadopentetic acid dimeglumine salt

Magnevist

Meglumine gadopentetate

SH L 451 A

SH-L 451 A

SH-L-451-A

SHL-451A

Status

Molecule Category

UNKNOWN

UNII

RH248G8V27


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C21H37GdN4O15
Molecular Weight	742.79
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C21H37GdN4O15

Molecular Weight

742.79

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Mechanism of Action	Action	Reference
Diagnostic agent	None	DailyMed

Mechanism of Action

Action

Reference

Diagnostic agent

None

DailyMed

Resources	Reference
ChEMBL	CHEMBL1200431
FDA SRS	RH248G8V27
PubChem	55466

Resources

Reference

ChEMBL

CHEMBL1200431

FDA SRS

RH248G8V27

PubChem

55466


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

GADOPENTETATE DIMEGLUMINE

Physicochemical Descriptors

Bioactivity

Cross References